A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-28 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
=== Trial === When the case reached the Old Bailey in September 1994, Mr Justice Ognall ruled that the police had shown "excessive zeal" and had tried to incriminate Stagg by "deceptive conduct of the grossest kind". He excluded all the entrapment evidence on the grounds that Stagg's descriptions of the murder were not nearly as close to the reality as the police had maintained. With no other evidence to present, the prosecution withdrew its case and Stagg was acquitted. Keith Pedder, the case's lead detective, received heavy public criticism. Even after Stagg was (rightfully as it later turned out) cleared of the murder of Nickell, Pedder continued over subsequent years to promote his theory that Stagg was guilty. He told an ITV Real Crime documentary in 2001:
=== Embryogenesis === In male mammals, AMH prevents the development of the Müllerian ducts into the uterus and other Müllerian structures. The effect is ipsilateral, that is each testis suppresses Müllerian development only on its own side. If no hormone is produced from the gonads, the Müllerian will develop thanks to the presence of Wnt4, while the Wolffian ducts, which are responsible for male reproductive parts, will die due to the presence of COUP-TFII. Amounts of AMH that are measurable in the blood vary by age and sex. AMH works by interacting with specific receptors on the surfaces of the cells of target tissues (anti-Müllerian hormone receptors). The best-known and most specific effect, mediated through the AMH type II receptors, includes programmed cell death (apoptosis) of the target tissue (the fetal Müllerian ducts). Phylogenetically, the amh gene first appears among cartilaginous fishes in line with the appearance of paired Müllerian ducts. In teleost fishes, there is no Müllerian duct, as male and female both develop gonoducts as a posterior extension of the gonads. Despite this, amh is expressed. During embryo development, the undifferentiated gonads express amh expression at low and equal levels for both sexes. Later, in males, amh expression increases and remains high during and after puberty in adults. In the female chicken embryo, the right duct and the right gonad regresses, both mediated by AMH, but the left duct remains, likely protected by estrogen.
Prior to the development of biological therapy as a modality to treat IBD, other medications that modulate the immune system—including 5-aminosalicylates, steroids, azathioprine, and other immunosuppressants—were primarily used in treatment. Corticosteroids are effective in inducing clinical remission in patients with active IBD, but they can't be used long term due to the risk of steroid-dependence and harsh side effects. The other medications like 5-aminosalicylates and azathioprine are often used to reduce steroid use while maintaining remission, but their actual effect on the state of the disease and the need for surgery remains unknown. Patients with Crohn's disease that developed complications, including fistulae (= abnormal connections to the bowel) were treated with surgery. Patients with ulcerative colitis who do not respond to medications are still treated with colectomy (= removal of the colon). However, basic science research showed that many cytokines were elevated in both Crohn's disease and ulcerative colitis. Crohn's disease cytokines are of the type 1 (Th1) cytokines, which include TNF-α, interleukin-2, and interferon γ. Ulcerative colitis was less conclusively linked to the production of Th2 cytokines. TNF inhibiting biological therapies were initially used in IBD patients who weren't responding to conventional therapy. They proved to be very effective in some patients, shifting treatment goals from simply improving symptoms to actually changing the course of the disease by reversing mucosal inflammation and preventing long-term complications and surgery.
1883. A Treatise on the Motion of Vortex Rings: An essay to which the Adams Prize was adjudged in 1882, in the University of Cambridge. London: Macmillan and Co., pp. 146. Recent reprint: ISBN 0-543-95696-2. 1888. Applications of Dynamics to Physics and Chemistry. London: Macmillan and Co., pp. 326. Recent reprint: ISBN 1-4021-8397-6. 1893. Notes on recent researches in electricity and magnetism: intended as a sequel to Professor Clerk-Maxwell's 'Treatise on Electricity and Magnetism'. Oxford University Press, pp. xvi & 578. 1991, Cornell University Monograph: ISBN 1-4297-4053-1. Thomson, Joseph John (1893). Notes on recent researches in electricity and magnetism. Oxford: Clarendon Press. Thomson, Joseph John (1900). Discharge of electricity through gases (in German). Leipzig: Johann Ambrosius Barth. Thomson, Joseph John (1904). Electricity and matter (in English). Oxford : Clarendon Press. Thomson, Joseph John (1905). Electricity and matter (in Italian). Milano: Hoepli. Thomson, Joseph John (1908). Corpuscular theory of matter (in German). Braunschweig: Vieweg und Sohn. 1921 (1895). Elements of the Mathematical Theory of Electricity And Magnetism. London: Macmillan and Co. Scan of 1895 edition. A Text book of Physics in Five Volumes, co-authored with J.H. Poynting: (1) Properties of Matter, (2) Sound, (3) Heat, (4) Light, and (5) Electricity and Magnetism. Dated 1901 and later, and with revised later editions. Dahl, Per F. (1997). Flash of the Cathode Rays: A History of J J Thomson's Electron. Bristol and Philadelphia: Institute of Physics Publishing. ISBN 0-7503-0453-7.
Sources: en.wikipedia.org
=== Astroglide === Invented at Edwards Air Force Base in 1977, Astroglide was intended to improve the heat transfer in the cooling system of the shuttle orbiter. Being water-soluble and non-toxic, the substance was repurposed and marketed as a personal lubricant.
=== Europe === An example from Europe is the implementation of border controls on travel to and from Svalbard, which maintains a policy of free migration under the Svalbard Treaty and the Schengen Area, which includes the rest of Norway. Other examples of effective internal border controls in Europe include the closed cities of certain CIS members, areas of Turkmenistan that require special permits to enter, restrictions on travel to the Gorno-Badakhshan Autonomous Region in Tajikistan, and (depending on whether Northern and Southern Cyprus are considered separate countries) the Cypriot border. Similarly, Iraq's Kurdistan region maintains a separate, more liberal visa and customs regime from the rest of the country, even allowing visa-free entry for Israelis, whilst the rest of the country bans them from entering. Denmark also maintains a complex system of subnational countries which, unlike the Danish mainland, are outside the European Union and maintain autonomous customs policies. In addition to the numerous closed cities of Russia, parts of 19 subjects of the Russian Federation are closed for foreigners without special permits and are consequently subject to internal border controls. Another complex border-control situation in Europe involves the United Kingdom. Whilst the crown dependencies are within the Common Travel Area, neither Gibraltar nor the sovereign British military exclaves of Akrotiri and Dhekelia are.
phenome The complete set of phenotypes that are or can be expressed by a genome, cell, tissue, organism, or species; the sum of all of its manifest chemical, morphological, and behavioral characteristics or traits.
in Ohm's law is sufficiently small relative to the other terms that it can be taken to be zero. This occurs in the limit of large magnetic Reynolds numbers, in which magnetic induction dominates magnetic diffusion at the velocity and length scales under consideration. Consequently, processes in ideal MHD that convert magnetic energy into kinetic energy, referred to as ideal processes, cannot generate heat or increase entropy. A fundamental concept underlying ideal MHD is the frozen-in flux theorem, which states that the bulk fluid and the embedded magnetic field are constrained to move together such that one can be said to be "tied" or "frozen" to the other. Therefore, any two points that move with the bulk fluid velocity and lie on the same magnetic field line will continue to lie on that field line even as the points are advected by fluid flows in the system. The connection between the fluid and magnetic field fixes the topology of the magnetic field in the fluid. For example, if a set of magnetic field lines is tied into a knot, then it will remain so as long as the fluid has negligible resistivity. This difficulty in reconnecting magnetic field lines makes it possible to store energy by moving the fluid or the source of the magnetic field. The energy can then become available if the conditions for ideal MHD break down, allowing magnetic reconnection to release the stored energy from the magnetic field.
=== Evolutionary dynamics === After formation, a hypercycle reaches either an internal equilibrium or a state with oscillating concentrations of each type of chain I, but with the total concentration of all chains remaining constant. In this way, the system consisting of all chains can be expressed as a single, integrated entity. During the formation of hypercycles, several of them could be present in comparable concentrations, but very soon, a selection of the hypercycle with the highest fitness value will take place. Here, the fitness value expresses the adaptation of the hypercycle to the environment, and the selection based on it is very sharp. After one hypercycle wins the competition, it is very unlikely that another one could take its place, even if the new hypercycle would be more efficient than the winner. Usually, even large fluctuations in the numbers of internal species cannot weaken the hypercycle enough to destroy it. In the case of a hypercycle, we can speak of one-for-ever selection, which is responsible for the existence of a unique translation code and a particular chirality. The above-described idea of a hypercycle's robustness results from an exponential growth of its constituents caused by the catalytic support. However, Eörs Szathmáry and Irina Gladkih showed that an unconditional coexistence can be obtained even in the case of a non-enzymatic template replication that leads to a subexponential or a parabolic growth. This could be observed during the stages preceding a catalytic replication that are necessary for the formation of hypercycles.
Sources: en.wikipedia.org
=== Polymers and coatings === IGC has been used extensively for the characterization of polymer films, beads, and powders. For instance, IGC was used to study surface properties and interactions amongst components in paint formulations. Also, IGC has been used to investigate the degree of crosslinking for ethylene propylene rubber using the Flory–Rehner equation [17]. Additionally, IGC is a sensitive technique for the detection and determination of first and second order phase transitions like melting and glass transition temperatures of polymers. Although other techniques like differential scanning calorimetry are capable of measuring these transition temperatures, IGC has the capability of glass transition temperatures as a function of relative humidity.
=== Exercise === While many environmental factors may exacerbate Parkinson's disease, exercise is considered to be one of the main protective factors for neurodegenerative disorders, including Parkinson's disease. The use of exercise can reduce risk or delay development of PD (primary prevention). Higher levels of moderate to vigorous physical activity are associated with a lowered risk of PD. There are also indications that exercise may slow or halt PD progression (secondary prevention). For example, increased levels of physical activity have been associated with slower deterioration on measures of daily living activities. This was found regardless of people's initial physical activity levels. Finally, exercise may help to reduce some symptoms of PD (tertiary prevention). Underlying protective mechanisms are not yet understood. Types of exercise that have been studied include aerobic exercise, resistance exercise, and balance and gait exercises. Respectively, they improve aerobic capacity, muscle strength, and postural stability/balance. Aerobic exercise includes physical activity that increases the heart rate. Resistance training uses tools like weights, bands, or bodyweight to challenge muscles, increasing strength and function over time. Goal-based exercises are often developed with the guidance of a physical therapist to target specific outcomes such as balance and gait.
=== Diet === American cockroaches are omnivorous and opportunistic feeders that eat materials such as cheese, sweets, beer, tea, leather, bakery products, starch in book bindings, manuscripts, glue, hair, flakes of dried skin, dead animals, plant materials, soiled clothing, and glossy paper with starch sizing. They are particularly fond of fermenting foods. They have also been observed to feed upon dead or wounded cockroaches of their own or other species.
== Equipment == In using form-fill-seal packaging machines, the main function is to place the product in a flexible pouch suitable for the desired characteristics of the final product. These pouches can either be pre-formed or thermoformed. The food is introduced into the pouch, the composition of the headspace atmosphere is changed within the package; it is then heat sealed. These types of machines are typically called pillow-wrap, which horizontally or vertically form, fill and seal the product. Form-fill-seal packaging machines are usually used for large scale operations. In contrast, chamber machines are used for batch processes. A filled pre-formed wrap is filled with the product and introduced into a cavity. The cavity is closed and vacuum is then pulled on the chamber and the modified atmosphere is inserted as desired. Sealing of the package is done through heated sealing bars, and the product is then removed. This batch process is labor-intensive and thus requires a longer period of time; however, it is relatively cheaper than packaging machines which are automated. Additionally, snorkel machines are used to modify the atmosphere within a package after the food has been filled. The product is placed in the packaging material and positioned into the machine without the need of a chamber. A nozzle, which is the snorkel, is then inserted into the packaging material. It pulls a vacuum and then flushes the modified atmosphere into the package. The nozzle is removed and the package is heat sealed. This method is suitable for bulk and large operations.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.